316 related articles for article (PubMed ID: 20361056)
21. TDP-43 expression in mouse models of amyotrophic lateral sclerosis and spinal muscular atrophy.
Turner BJ; Bäumer D; Parkinson NJ; Scaber J; Ansorge O; Talbot K
BMC Neurosci; 2008 Oct; 9():104. PubMed ID: 18957104
[TBL] [Abstract][Full Text] [Related]
22. The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia.
Mackenzie IR; Rademakers R
Curr Opin Neurol; 2008 Dec; 21(6):693-700. PubMed ID: 18989115
[TBL] [Abstract][Full Text] [Related]
23. Rapamycin alleviates pathogenesis of a new Drosophila model of ALS-TDP.
Cheng CW; Lin MJ; Shen CK
J Neurogenet; 2015; 29(2-3):59-68. PubMed ID: 26219309
[TBL] [Abstract][Full Text] [Related]
24. A robust TDP-43 knock-in mouse model of ALS.
Huang SL; Wu LS; Lee M; Chang CW; Cheng WC; Fang YS; Chen YR; Cheng PL; Shen CJ
Acta Neuropathol Commun; 2020 Jan; 8(1):3. PubMed ID: 31964415
[TBL] [Abstract][Full Text] [Related]
25. [Clinical and pathological spectrum of TDP-43 associated ALS].
Onodera O; Yokoseki A; Tan CF; Ishihara T; Nishiira Y; Toyoshima Y; Kakita A; Nishizawa M; Takahashi H
Rinsho Shinkeigaku; 2010 Nov; 50(11):940-2. PubMed ID: 21921519
[TBL] [Abstract][Full Text] [Related]
26. The vulnerability of motor and frontal cortex-dependent behaviors in mice expressing ALS-linked mutation in TDP-43.
Wong P; Ho WY; Yen YC; Sanford E; Ling SC
Neurobiol Aging; 2020 Aug; 92():43-60. PubMed ID: 32422502
[TBL] [Abstract][Full Text] [Related]
27. TDP-43-M323K causes abnormal brain development and progressive cognitive and motor deficits associated with mislocalised and increased levels of TDP-43.
Godoy-Corchuelo JM; Ali Z; Brito Armas JM; Martins-Bach AB; García-Toledo I; Fernández-Beltrán LC; López-Carbonero JI; Bascuñana P; Spring S; Jimenez-Coca I; Muñoz de Bustillo Alfaro RA; Sánchez-Barrena MJ; Nair RR; Nieman BJ; Lerch JP; Miller KL; Ozdinler HP; Fisher EMC; Cunningham TJ; Acevedo-Arozena A; Corrochano S
Neurobiol Dis; 2024 Apr; 193():106437. PubMed ID: 38367882
[TBL] [Abstract][Full Text] [Related]
28. Mutant UBQLN2
Chen T; Huang B; Shi X; Gao L; Huang C
Acta Neuropathol Commun; 2018 Nov; 6(1):122. PubMed ID: 30409191
[TBL] [Abstract][Full Text] [Related]
29. Human TDP-43 and FUS selectively affect motor neuron maturation and survival in a murine cell model of ALS by non-cell-autonomous mechanisms.
Wächter N; Storch A; Hermann A
Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(7-8):431-41. PubMed ID: 26174443
[TBL] [Abstract][Full Text] [Related]
30. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43.
Arnold ES; Ling SC; Huelga SC; Lagier-Tourenne C; Polymenidou M; Ditsworth D; Kordasiewicz HB; McAlonis-Downes M; Platoshyn O; Parone PA; Da Cruz S; Clutario KM; Swing D; Tessarollo L; Marsala M; Shaw CE; Yeo GW; Cleveland DW
Proc Natl Acad Sci U S A; 2013 Feb; 110(8):E736-45. PubMed ID: 23382207
[TBL] [Abstract][Full Text] [Related]
31. TDP-43-mediated neurodegeneration: towards a loss-of-function hypothesis?
Vanden Broeck L; Callaerts P; Dermaut B
Trends Mol Med; 2014 Feb; 20(2):66-71. PubMed ID: 24355761
[TBL] [Abstract][Full Text] [Related]
32. [TDP-43 proteinopathies: ALS and frontotemporal dementias].
Prudlo J
Fortschr Neurol Psychiatr; 2009 Aug; 77 Suppl 1():S25-7. PubMed ID: 19685386
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of ALS-associated p.M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice.
Janssens J; Wils H; Kleinberger G; Joris G; Cuijt I; Ceuterick-de Groote C; Van Broeckhoven C; Kumar-Singh S
Mol Neurobiol; 2013 Aug; 48(1):22-35. PubMed ID: 23475610
[TBL] [Abstract][Full Text] [Related]
34. Clinical and neuropathological features of ALS/FTD with TIA1 mutations.
Hirsch-Reinshagen V; Pottier C; Nicholson AM; Baker M; Hsiung GR; Krieger C; Sengdy P; Boylan KB; Dickson DW; Mesulam M; Weintraub S; Bigio E; Zinman L; Keith J; Rogaeva E; Zivkovic SA; Lacomis D; Taylor JP; Rademakers R; Mackenzie IRA
Acta Neuropathol Commun; 2017 Dec; 5(1):96. PubMed ID: 29216908
[TBL] [Abstract][Full Text] [Related]
35. Enhancing survival motor neuron expression extends lifespan and attenuates neurodegeneration in mutant TDP-43 mice.
Perera ND; Sheean RK; Crouch PJ; White AR; Horne MK; Turner BJ
Hum Mol Genet; 2016 Sep; 25(18):4080-4093. PubMed ID: 27466204
[TBL] [Abstract][Full Text] [Related]
36. Altered astrocytic expression of TDP-43 does not influence motor neuron survival.
Haidet-Phillips AM; Gross SK; Williams T; Tuteja A; Sherman A; Ko M; Jeong YH; Wong PC; Maragakis NJ
Exp Neurol; 2013 Dec; 250():250-9. PubMed ID: 24120466
[TBL] [Abstract][Full Text] [Related]
37. Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS.
Robertson J; Sanelli T; Xiao S; Yang W; Horne P; Hammond R; Pioro EP; Strong MJ
Neurosci Lett; 2007 Jun; 420(2):128-32. PubMed ID: 17543992
[TBL] [Abstract][Full Text] [Related]
38. Mitigation of TDP-43 toxic phenotype by an RGNEF fragment in amyotrophic lateral sclerosis models.
Droppelmann CA; Campos-Melo D; Noches V; McLellan C; Szabla R; Lyons TA; Amzil H; Withers B; Kaplanis B; Sonkar KS; Simon A; Buratti E; Junop M; Kramer JM; Strong MJ
Brain; 2024 Jun; 147(6):2053-2068. PubMed ID: 38739752
[TBL] [Abstract][Full Text] [Related]
39. Similar dose-dependence of motor neuron cell death caused by wild type human TDP-43 and mutants with ALS-associated amino acid substitutions.
Wu LS; Cheng WC; Shen CK
J Biomed Sci; 2013 May; 20(1):33. PubMed ID: 23721326
[TBL] [Abstract][Full Text] [Related]
40. Genetic strategies to study TDP-43 in rodents and to develop preclinical therapeutics for amyotrophic lateral sclerosis.
Wang DB; Gitcho MA; Kraemer BC; Klein RL
Eur J Neurosci; 2011 Oct; 34(8):1179-88. PubMed ID: 21777407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
